These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 39232192)

  • 1. Will esaxerenone be added to the antihypertensive treatment strategy of practicing physicians as a second-line antihypertensive drug?
    Yoshida T
    Hypertens Res; 2024 Sep; 47(9):2574-2576. PubMed ID: 39232192
    [No Abstract]   [Full Text] [Related]  

  • 2. Home blood pressure-lowering effect of a non-steroidal mineralocorticoid receptor blocker, esaxerenone, versus trichlormethiazide for uncontrolled hypertension: the EXCITE-HT randomized controlled study.
    Kario K; Ohbayashi H; Hashimoto M; Itabashi N; Kato M; Uchiyama K; Hirano K; Nakamura N; Miyamoto T; Nagashima H; Kajiyama S; Ishida H; Imai E; Ebe Y; Ohishi M; Katsuya T; Taguchi T; Tanabe A; Shimosawa T;
    Hypertens Res; 2024 Sep; 47(9):2435-2446. PubMed ID: 39039285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension.
    Rakugi H; Ito S; Itoh H; Okuda Y; Yamakawa S
    Hypertens Res; 2019 Dec; 42(12):1932-1941. PubMed ID: 31554937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats.
    Li L; Guan Y; Kobori H; Morishita A; Kobara H; Masaki T; Nakano D; Nishiyama A
    Hypertens Res; 2019 Jun; 42(6):769-778. PubMed ID: 30587856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study.
    Ito S; Itoh H; Rakugi H; Okuda Y; Yamakawa S
    J Hum Hypertens; 2019 Jul; 33(7):542-551. PubMed ID: 31113987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker.
    Arai K; Morikawa Y; Ubukata N; Sugimoto K
    Hypertens Res; 2020 Nov; 43(11):1204-1213. PubMed ID: 32616846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study).
    Ito S; Itoh H; Rakugi H; Okuda Y; Yoshimura M; Yamakawa S
    Hypertension; 2020 Jan; 75(1):51-58. PubMed ID: 31786983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice.
    Bhuiyan AS; Rafiq K; Kobara H; Masaki T; Nakano D; Nishiyama A
    Hypertens Res; 2019 Jun; 42(6):892-902. PubMed ID: 30664703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esaxerenone: First Global Approval.
    Duggan S
    Drugs; 2019 Mar; 79(4):477-481. PubMed ID: 30806972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of a multicenter randomized study comparing the efficacy and safety of esaxerenone versus trichlormethiazide in patients with uncontrolled essential hypertension: EXCITE-HT study.
    Kario K; Ohishi M; Katsuya T; Taguchi T; Tanabe A; Sugimoto K; Shimosawa T
    J Clin Hypertens (Greenwich); 2023 Sep; 25(9):861-867. PubMed ID: 37551054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone.
    Rakugi H; Yamakawa S; Sugimoto K
    Hypertens Res; 2021 Apr; 44(4):371-385. PubMed ID: 33214722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacological profile, clinical efficacy, and safety of esaxerenone (Minnebro
    Yamakawa S; Homma T; Yamada M; Igawa Y; Yoshimura M
    Nihon Yakurigaku Zasshi; 2020; 155(5):340-350. PubMed ID: 32879177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihypertensive Effect of Long-Term Monotherapy with Esaxerenone in Patients with Essential Hypertension: Relationship Between Baseline Urinary Sodium Excretion and Its Antihypertensive Effect.
    Ichikawa S; Tsutsumi J; Sugimoto K; Yamakawa S
    Adv Ther; 2022 Oct; 39(10):4779-4791. PubMed ID: 35976603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploratory study on the relationship between urinary sodium/potassium ratio, salt intake, and the antihypertensive effect of esaxerenone: the ENaK Study.
    Katsuya T; Inobe Y; Uchiyama K; Nishikawa T; Hirano K; Kato M; Fukui T; Hatta T; Iwasaki A; Ishii H; Sugiura T; Taguchi T; Tanabe A; Sugimoto K; Shimosawa T;
    Hypertens Res; 2024 Apr; 47(4):835-848. PubMed ID: 38212366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Pharmacokinetics and Pharmacodynamics of Esaxerenone, a Novel Mineralocorticoid Receptor Antagonist: A Review.
    Janković SM; Janković SV
    Eur J Drug Metab Pharmacokinet; 2022 May; 47(3):291-308. PubMed ID: 35190999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats.
    Rahman A; Sawano T; Sen A; Hossain A; Jahan N; Kobara H; Masaki T; Kosaka S; Kitada K; Nakano D; Imamura T; Ohsaki H; Nishiyama A
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Esaxerenone: blood pressure reduction and cardiorenal protection without reflex sympathetic activation in salt-loaded stroke-prone spontaneously hypertensive rats.
    Ikeda S; Shinohara K; Kashihara S; Matsumoto S; Yoshida D; Nakashima R; Ono Y; Matsushima S; Tsutsui H; Kinugawa S
    Hypertens Res; 2024 Aug; 47(8):2133-2143. PubMed ID: 38802501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: A retrospective study.
    Iwahana T; Saito Y; Okada S; Kato H; Ono R; Kobayashi Y
    PLoS One; 2021; 16(11):e0259485. PubMed ID: 34748605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction.
    Ito S; Itoh H; Rakugi H; Okuda Y; Iijima S
    Hypertens Res; 2021 May; 44(5):489-497. PubMed ID: 33323991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is esaxerenone the ultimate mineralocorticoid receptor antagonist?
    Hoshide S
    Hypertens Res; 2023 Feb; 46(2):516-517. PubMed ID: 36289363
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.